Eisai subsidiary H3 Biomedicine said today it has extended its more than 2-year-old collaboration with Foundation Medicine to discover and develop precision medicines in oncology.
The value of the expanded collaboration was not disclosed.
H3 is a member of Eisai’s global Oncology Business Group focused on cancer genomics based drug discovery by developing small molecules for cancer treatment. H3 and Foundation Medicine launched their collaboration in February 2015, joining Foundation Medicine’s FoundationCORE™ genomic dataset with H3 Biomedicine’s drug discovery engine and computational biology platform.
FoundationCORE contains more than 100,000 real-world, clinical genomic profiles, Foundation Medicine stated in its Form 10-K Annual Report for 2016, filed March 3 with the U.S. Securities and Exchange Commission.
“The genomics data in FoundationCORE is a better reflection of patients seeking treatment in current clinical practice compared with publicly available data sets, and it will continue to evolve as new therapies are adopted,” Lihua Yu, Ph.D., vp of data science and IT at H3, said in a statement. “Thorough computational analysis beyond variant calls allows us to connect genomic aberrations with disease context, which can directly impact the trajectory of our pipeline.”
H3 and Foundation Medicine said they will build upon the progress they have made during the collaboration, but offered no details of that progress in today’s announcement.
The companies have agreed to continue expanding the translation of ongoing H3 programs and identifying new, actionable cancer drivers by applying data from FoundationCORE, H3 said.
“Having access, through Foundation Medicine, to a high-quality, large-scale dataset for identification of novel driver events and clinical translation helps create a competitive edge for H3 within the current oncology drug development market,” added H3’s president and CEO Markus Warmuth, M.D. “The collaboration with Foundation Medicine has broadened the scope of our clinical programs and has pointed us in new, unique directions and we look forward to continuing this successful collaboration.”
H3 is one of more than 30 biopharmaceutical partners with which Foundation Medicine has ongoing relationships. Many of those companies, like H3, are developers of targeted cancer therapies. Other Foundation Medicine partners include Agios, ARIAD Pharmaceuticals (now a wholly owned subsidiary of Takeda Pharmacentical), Array BioPharma, AstraZeneca, Clovis Oncology, Loxo, Johnson & Johnson, Mirati, Novartis, and Roche.